[{"orgOrder":0,"company":"BPGbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"aldosterone antagonists (spironolactone type)","graph1":"Oncology","graph2":"Phase II","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BPGbio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BPGbio \/ Undisclosed"},{"orgOrder":0,"company":"BPGbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"aldosterone antagonists (spironolactone type)","graph1":"Undisclosed","graph2":"Phase I","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"BPGbio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BPGbio \/ Undisclosed"},{"orgOrder":0,"company":"BPGbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"aldosterone antagonists (spironolactone type)","graph1":"Undisclosed","graph2":"Phase I","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"BPGbio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BPGbio \/ Undisclosed"},{"orgOrder":0,"company":"BPGbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"aldosterone antagonists (spironolactone type)","graph1":"Oncology","graph2":"Phase II","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"BPGbio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BPGbio \/ Undisclosed"},{"orgOrder":0,"company":"PharmEvo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"PAKISTAN","productType":"Enzyme","year":"2017","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"PharmEvo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmEvo \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"PharmEvo \/ Undisclosed"},{"orgOrder":0,"company":"Aarhus University Hospital","sponsor":"University of Aarhus | Pharma Nord","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Aarhus University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aarhus University Hospital \/ University of Aarhus | Pharma Nord","highestDevelopmentStatusID":"8","companyTruncated":"Aarhus University Hospital \/ University of Aarhus | Pharma Nord"},{"orgOrder":0,"company":"Hospital Universitari Vall d'Hebron Research Institute","sponsor":"Vitae Health Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Enzyme","year":"2017","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hospital Universitari Vall d'Hebron Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Universitari Vall d'Hebron Research Institute \/ Vitae Health Innovation","highestDevelopmentStatusID":"1","companyTruncated":"Hospital Universitari Vall d'Hebron Research Institute \/ Vitae Health Innovation"},{"orgOrder":0,"company":"Qunol","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Acquisition","leadProduct":"Coenzyme Q10","moa":"||Mitochondrial electron transport chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Qunol","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Qunol \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Qunol \/ Sanofi"},{"orgOrder":0,"company":"Qunol","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Acquisition","leadProduct":"Coenzyme Q10","moa":"||Mitochondrial electron transport chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Qunol","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Qunol \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Qunol \/ Sanofi"},{"orgOrder":0,"company":"University of Toronto","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"University of Toronto","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Toronto \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Toronto \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Kaneka Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Enzyme","year":"2014","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Kaneka Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Massachusetts General Hospital \/ Kaneka Corporation"},{"orgOrder":0,"company":"Kaneka Nutrients","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Kaneka Nutrients","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaneka Nutrients \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kaneka Nutrients \/ Undisclosed"},{"orgOrder":0,"company":"McGill University","sponsor":"Clarus","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"CANADA","productType":"Enzyme","year":"2021","type":"Licensing Agreement","leadProduct":"Coenzyme Q10","moa":"||Mitochondrial electron transport chain","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"McGill University","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"McGill University \/ Clarus","highestDevelopmentStatusID":"1","companyTruncated":"McGill University \/ Clarus"},{"orgOrder":0,"company":"Tor Biering-S\u00f8rensen","sponsor":"Pharma Nord","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Tor Biering-S\u00f8rensen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tor Biering-S\u00f8rensen \/ Pharma Nord","highestDevelopmentStatusID":"10","companyTruncated":"Tor Biering-S\u00f8rensen \/ Pharma Nord"},{"orgOrder":0,"company":"Cooperative International Neuromuscular Research Group","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Cooperative International Neuromuscular Research Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cooperative International Neuromuscular Research Group \/ US Department of Defense","highestDevelopmentStatusID":"9","companyTruncated":"Cooperative International Neuromuscular Research Group \/ US Department of Defense"},{"orgOrder":0,"company":"VIST","sponsor":"European Regional Development Fund | Valens Int. d.o.o., Slovenija | Ministry of Education, Science and Sport, Republic of Slovenia","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Enzyme","year":"2019","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"VIST","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VIST \/ European Regional Development Fund | Valens Int. d.o.o., Slovenija | Ministry of Education, Science and Sport, Republic of Slovenia","highestDevelopmentStatusID":"1","companyTruncated":"VIST \/ European Regional Development Fund | Valens Int. d.o.o., Slovenija | Ministry of Education, Science and Sport, Republic of Slovenia"},{"orgOrder":0,"company":"Comenius University","sponsor":"Kaneka Pharma Europe N.V. | Sanat\u00f3rium of Dr. Guhr, n.o.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SLOVAKIA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Comenius University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Comenius University \/ Kaneka Pharma Europe N.V. | Sanat\u00f3rium of Dr. Guhr, n.o.","highestDevelopmentStatusID":"1","companyTruncated":"Comenius University \/ Kaneka Pharma Europe N.V. | Sanat\u00f3rium of Dr. Guhr, n.o."},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Kaneka Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2013","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Beth Israel Deaconess Medical Center \/ Kaneka Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Beth Israel Deaconess Medical Center \/ Kaneka Corporation"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Kaneka Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Beth Israel Deaconess Medical Center \/ Kaneka Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Beth Israel Deaconess Medical Center \/ Kaneka Corporation"},{"orgOrder":0,"company":"University of Primorska","sponsor":"Biovis d.o.o.","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SLOVENIA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"University of Primorska","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Primorska \/ Biovis d.o.o.","highestDevelopmentStatusID":"1","companyTruncated":"University of Primorska \/ Biovis d.o.o."},{"orgOrder":0,"company":"Hospital Universitari Vall d'Hebron Research Institute","sponsor":"Pharma Nord","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial; Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial","graph1":"Immunology","graph2":"Undisclosed","graph3":"Hospital Universitari Vall d'Hebron Research Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Universitari Vall d'Hebron Research Institute \/ Pharma Nord","highestDevelopmentStatusID":"1","companyTruncated":"Hospital Universitari Vall d'Hebron Research Institute \/ Pharma Nord"},{"orgOrder":0,"company":"VISUfarma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Enzyme","year":"2019","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial; Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"VISUfarma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VISUfarma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"VISUfarma \/ Undisclosed"},{"orgOrder":0,"company":"Factors Group of Nutritional Companies Inc.","sponsor":"Isura","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial; Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Factors Group of Nutritional Companies Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Factors Group of Nutritional Companies Inc. \/ Isura","highestDevelopmentStatusID":"1","companyTruncated":"Factors Group of Nutritional Companies Inc. \/ Isura"},{"orgOrder":0,"company":"BPGbio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BPGbio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BPGbio \/ Undisclosed"},{"orgOrder":0,"company":"BPGbio","sponsor":"Shasa Hu","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"aldosterone antagonists (spironolactone type)","graph1":"Rare Diseases and Disorders","graph2":"Phase I","graph3":"BPGbio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"BPGbio \/ Shasa Hu","highestDevelopmentStatusID":"6","companyTruncated":"BPGbio \/ Shasa Hu"}]
Find Clinical Drug Pipeline Developments & Deals for Neuquinon
Details :
Coenzyme Q10 is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Failure.
Details :
Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the US.
Details :
Through the acquisition, addition of Qunol’s CoQ10 (ubiquinone) and Turmeric products strengthens Sanofi’s CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the U.S.
Details :
Under the licensing agreement Clarus will develop and commercialize McGill’s proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans with Coenzyme-Q10 (Ubiquinone).
Details :
BPM31510 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glioblastoma.
Reset All
